Viracta Therapeutics

We are pleased to announce the initiation of NAVAL-1, a global pivotal trial for the treatment of relapsed/refractory Epstein-Barr Virus-Positive lymphoma. The study is now open for enrollment! bit.ly/3fEgZpx #clinicaltrials #EBV #Viracta #lymphoma

Thank you to Dylan James & @Nasdaq for inviting Viracta to ring the closing bell today! We look forward to advancing our clinical programs for the treatment of virus-associated cancers. This was a great way to celebrate! bit.ly/3qCkxeb #Viracta #Nasdaq #biopharma

We're thrilled to announce the management promotions of Shelly Vandertie to Vice President, Finance, Michael Mueller to Vice President, Legal Affairs and General Counsel and Dan Chevallard to Chief Operating Officer and Chief Financial Officer. prn.to/3uOPeQZ #Viracta

We’re pleased to strengthen Viracta’s leadership with the appointments of Stephen Rubino, Ph.D., MBA and Barry J. Simon, M.D. to the Board of Directors and Cheryl A. Madsen, RAC as Senior Vice President, Regulatory Affairs. prn.to/3uOPeQZ #Viracta #leadership #biopharma

We’re excited to be a publicly traded company on @Nasdaq! Great to see our logo up in Time Square! #Viracta #EBV #lymphoma #oncology #biopharma

We are excited to become a publicly traded company and begin trading on Nasdaq under the ticker symbol VIRX. prn.to/2ZLC6NU #Viracta #EBV #lymphoma #oncology #biopharma

We’re thrilled to announce the closing of Viracta’s merger with @SunesisPharma and our $65M Private Placement, which gives over $120M to advance our oral combination therapy for virus-associated malignancies! prn.to/2ZLC6NU #Viracta #EBV #lymphoma #oncology #biopharma

We are pleased to announce updated Phase 2 data at ASH 2020 & productive outcome of end of Ph 2 mtg with FDA. prn.to/3gifWdQ Data demonstrated promising results, 80%/40% ORR/CR rate in R/R EBV+ T-cell lymphoma patients & 66%/33% in DLBCL patients. #ASHFromHome #ASH20

Tune in to hear Viracta's CEO, Ivor Royston, MD, and Sunesis' Interim CEO Dayton Misfeldt, discuss the merger agreement today at 8:30am ET. bit.ly/3qfnoek #Viracta #EBV #lymphoma #oncology #biopharma

Today's merger agreement will allow us to advance and expand our clinical stage, precision oncology pipeline targeting virus-associated malignancies, including our lead program for the treatment of EBV-positive relapsed/refractory lymphomas. bit.ly/3o6Q9b8 #Viracta #EBV

We're thrilled to announce a definitive merger agreement with Sunesis Pharmaceuticals! When the merger closes, Viracta will be a publicly traded company on @Nasdaqglobalmarket under the ticker symbol "VIRX" w/ $120M to advance our pipeline. bit.ly/3o6Q9b8 #Viracta #EBV

Viracta CEO Ivor Royston will present a corporate overview at the Solebury Trout Fall Private Company Showcase on Thursday, October 15, 2020 at 1:00 pm ET. prn.to/36OCAaS #biotech #pharma

Viracta announces the appointment of Mark A. McCamish, MD, PhD as Strategic Advisor prn.to/2ZLI7va #EBV #lymphoma #oncology #medicine #biopharma

Viracta Therapeutics announces appointment of Roger J. Pomerantz, MD to its Board of Directors bit.ly/3j22zPO #EBV #lymphoma #oncology #medicine #biopharma

Viracta Therapeutics announces orphan drug designation granted for the treatment of T-cell lymphoma prn.to/3ewwahJ #EBV #lymphoma #oncology #medicine #biopharma

Join us June 5th for a #Viracta KOL call event! prn.to/2Bdjq0L Tune in to the webcast to hear guest speakers Dr. Ron Levy of @StanfordCancer and Dr. Pierluigi Porcu of @KimmelCancerCtr to discuss treatment of EBV-associated lymphoma #EBV #oncology #lymphoma

Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas prn.to/2VgaCxt #EBV #cancer #cancerresearch #biopharma #biomed #viralmalignancies #viracta

Viracta is pleased to announce the appointment of Lisa Rojkjaer, MD, as Chief Medical Officer bit.ly/2Jd4wrR #biopharma #biomed #cancerresearch #viralmalignancies #viracta